Biologic Therapeutic Drug - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511249206

Publication Date:

November 27, 2024

Pages:

104

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Biologic Therapeutic Drug are used for treatment of numerous diseases and conditions, and are the most advanced therapies.
The global market for Biologic Therapeutic Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologic Therapeutic Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biologic Therapeutic Drug by region & country, by Type, and by Application.
The Biologic Therapeutic Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologic Therapeutic Drug.
麻豆原创 Segmentation
By Company
Aurobindo Pharma Ltd.
Concord Biotech
GlaxoSmithKline Plc.
H. Lundbeck A/S
Novartis Global
Retractable Technologies, Inc.
Smith Medical
AstraZeneca
Pfizer Inc.
Merck and Co. Inc.
Segment by Type:
Monoclonal Antibodies
Therapeutic Proteins
Vaccines
Segment by Application
Clinical Medicine
Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biologic Therapeutic Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biologic Therapeutic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biologic Therapeutic Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Biologic Therapeutic Drug Product Introduction
1.2 Global Biologic Therapeutic Drug 麻豆原创 Size Forecast
1.3 Biologic Therapeutic Drug 麻豆原创 Trends & Drivers
1.3.1 Biologic Therapeutic Drug Industry Trends
1.3.2 Biologic Therapeutic Drug 麻豆原创 Drivers & Opportunity
1.3.3 Biologic Therapeutic Drug 麻豆原创 Challenges
1.3.4 Biologic Therapeutic Drug 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biologic Therapeutic Drug Players Revenue Ranking (2023)
2.2 Global Biologic Therapeutic Drug Revenue by Company (2019-2024)
2.3 Key Companies Biologic Therapeutic Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Biologic Therapeutic Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Biologic Therapeutic Drug
2.6 Biologic Therapeutic Drug 麻豆原创 Competitive Analysis
2.6.1 Biologic Therapeutic Drug 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Biologic Therapeutic Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologic Therapeutic Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monoclonal Antibodies
3.1.2 Therapeutic Proteins
3.1.3 Vaccines
3.2 Global Biologic Therapeutic Drug Sales Value by Type
3.2.1 Global Biologic Therapeutic Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Biologic Therapeutic Drug Sales Value, by Type (2019-2030)
3.2.3 Global Biologic Therapeutic Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinical Medicine
4.1.2 Laboratory
4.1.3 Others
4.2 Global Biologic Therapeutic Drug Sales Value by Application
4.2.1 Global Biologic Therapeutic Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Biologic Therapeutic Drug Sales Value, by Application (2019-2030)
4.2.3 Global Biologic Therapeutic Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Biologic Therapeutic Drug Sales Value by Region
5.1.1 Global Biologic Therapeutic Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Biologic Therapeutic Drug Sales Value by Region (2019-2024)
5.1.3 Global Biologic Therapeutic Drug Sales Value by Region (2025-2030)
5.1.4 Global Biologic Therapeutic Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Biologic Therapeutic Drug Sales Value, 2019-2030
5.2.2 North America Biologic Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Biologic Therapeutic Drug Sales Value, 2019-2030
5.3.2 Europe Biologic Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Biologic Therapeutic Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Biologic Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Biologic Therapeutic Drug Sales Value, 2019-2030
5.5.2 South America Biologic Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Biologic Therapeutic Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Biologic Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biologic Therapeutic Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Biologic Therapeutic Drug Sales Value
6.3 United States
6.3.1 United States Biologic Therapeutic Drug Sales Value, 2019-2030
6.3.2 United States Biologic Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Biologic Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Biologic Therapeutic Drug Sales Value, 2019-2030
6.4.2 Europe Biologic Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Biologic Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Biologic Therapeutic Drug Sales Value, 2019-2030
6.5.2 China Biologic Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Biologic Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Biologic Therapeutic Drug Sales Value, 2019-2030
6.6.2 Japan Biologic Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Biologic Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Biologic Therapeutic Drug Sales Value, 2019-2030
6.7.2 South Korea Biologic Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Biologic Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Biologic Therapeutic Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Biologic Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Biologic Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Biologic Therapeutic Drug Sales Value, 2019-2030
6.9.2 India Biologic Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Biologic Therapeutic Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Aurobindo Pharma Ltd.
7.1.1 Aurobindo Pharma Ltd. Profile
7.1.2 Aurobindo Pharma Ltd. Main Business
7.1.3 Aurobindo Pharma Ltd. Biologic Therapeutic Drug Products, Services and Solutions
7.1.4 Aurobindo Pharma Ltd. Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.1.5 Aurobindo Pharma Ltd. Recent Developments
7.2 Concord Biotech
7.2.1 Concord Biotech Profile
7.2.2 Concord Biotech Main Business
7.2.3 Concord Biotech Biologic Therapeutic Drug Products, Services and Solutions
7.2.4 Concord Biotech Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.2.5 Concord Biotech Recent Developments
7.3 GlaxoSmithKline Plc.
7.3.1 GlaxoSmithKline Plc. Profile
7.3.2 GlaxoSmithKline Plc. Main Business
7.3.3 GlaxoSmithKline Plc. Biologic Therapeutic Drug Products, Services and Solutions
7.3.4 GlaxoSmithKline Plc. Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.3.5 H. Lundbeck A/S Recent Developments
7.4 H. Lundbeck A/S
7.4.1 H. Lundbeck A/S Profile
7.4.2 H. Lundbeck A/S Main Business
7.4.3 H. Lundbeck A/S Biologic Therapeutic Drug Products, Services and Solutions
7.4.4 H. Lundbeck A/S Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.4.5 H. Lundbeck A/S Recent Developments
7.5 Novartis Global
7.5.1 Novartis Global Profile
7.5.2 Novartis Global Main Business
7.5.3 Novartis Global Biologic Therapeutic Drug Products, Services and Solutions
7.5.4 Novartis Global Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Novartis Global Recent Developments
7.6 Retractable Technologies, Inc.
7.6.1 Retractable Technologies, Inc. Profile
7.6.2 Retractable Technologies, Inc. Main Business
7.6.3 Retractable Technologies, Inc. Biologic Therapeutic Drug Products, Services and Solutions
7.6.4 Retractable Technologies, Inc. Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Retractable Technologies, Inc. Recent Developments
7.7 Smith Medical
7.7.1 Smith Medical Profile
7.7.2 Smith Medical Main Business
7.7.3 Smith Medical Biologic Therapeutic Drug Products, Services and Solutions
7.7.4 Smith Medical Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.7.5 Smith Medical Recent Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Profile
7.8.2 AstraZeneca Main Business
7.8.3 AstraZeneca Biologic Therapeutic Drug Products, Services and Solutions
7.8.4 AstraZeneca Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.8.5 AstraZeneca Recent Developments
7.9 Pfizer Inc.
7.9.1 Pfizer Inc. Profile
7.9.2 Pfizer Inc. Main Business
7.9.3 Pfizer Inc. Biologic Therapeutic Drug Products, Services and Solutions
7.9.4 Pfizer Inc. Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.9.5 Pfizer Inc. Recent Developments
7.10 Merck and Co. Inc.
7.10.1 Merck and Co. Inc. Profile
7.10.2 Merck and Co. Inc. Main Business
7.10.3 Merck and Co. Inc. Biologic Therapeutic Drug Products, Services and Solutions
7.10.4 Merck and Co. Inc. Biologic Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.10.5 Merck and Co. Inc. Recent Developments
8 Industry Chain Analysis
8.1 Biologic Therapeutic Drug Industrial Chain
8.2 Biologic Therapeutic Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biologic Therapeutic Drug Sales Model
8.5.2 Sales Channel
8.5.3 Biologic Therapeutic Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Aurobindo Pharma Ltd.
Concord Biotech
GlaxoSmithKline Plc.
H. Lundbeck A/S
Novartis Global
Retractable Technologies, Inc.
Smith Medical
AstraZeneca
Pfizer Inc.
Merck and Co. Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.